menu search

Syros: multiple shots on goal in blood cancer space

Final results from pivotal study SELECT-MDS-1, using Tamibarotene for the treatment of patients with newly diagnosed high-risk MDS that have RARA gene...

February 8, 2023, 10:10 am

Hillstream biopharma to host virtual r&d day to showcase its emerging immuno-oncology pipeline targeting drug-resistant cancers

Quatramer-based HSB-1216 combined with anti-MUC1-C antibody designed to target cancer stem cells (CSCs)...

February 6, 2023, 12:00 pm

cancer support community applauds cancer moonshot’s achievements on one-year anniversary

WASHINGTON, D.C., Feb. 03, 2023 (GLOBE NEWSWIRE) — The cancer support Community (CSC), the world’s ...

February 3, 2023, 6:26 pm

Investing in cancer stocks

Learn about some of the leading cancer stocks in the U.S stock market this year....

January 30, 2023, 10:43 am

Briacell therapeutics: fast-tracking high-potential breast cancer immunotherapy

BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast ...

January 30, 2023, 8:02 am

Goodbody health to offer multi-cancer screening services via liquid biopsy test

Goodbody Health Ltd (AQSE:GDBY, OTCQB:GDBYF) said its network of UK clinics will start offering multi-cancer s...

January 26, 2023, 10:03 am

Better long-term buy in 2023: exact sciences or veracyte?

As cancer screenings are becoming covered more often, both companies stand to gain....

January 24, 2023, 10:23 am

cancer support community addresses elevated need for mental healthcare with new mental health programs and initiatives

The expanded resources respond to findings from research on cancer and mental health WASHINGTON, D.C., Jan. 23, 2023 (GLOBE NEWSWIRE) — ...

January 23, 2023, 8:57 pm

Biomea (bmea) begins dosing in lung cancer study, stock up

Biomea Fusion (BMEA) announces the successful dosing of the first patient in phase I/Ib study of BMF-219 in KRAS mutant solid tumors. Stocks rise 11.6...

January 18, 2023, 12:48 pm

Volitionrx announces expansion of availability of nu.q vet cancer test availability through idexx's reference laboratory network

VolitionRx Ltd (NYSE-A:VNRX) has announced the availability of its Nu.Q Vet Cancer Test through the IDEXX Laboratories Inc reference laboratory netwo...

January 12, 2023, 9:23 am

Novocure: catalysts stacking for more upside

Powered by the robust Phase 3 (LUNAR) trial, NovoCure Limited shares recently rallied over 70% in one trading session. You can expect Tumor Treating F...

January 9, 2023, 1:07 pm

Exact sciences raises fourth-quarter estimates above expectations

EXAS stock jumped as the provider of cancer screening and diagnostic tests raised estimates for its fou...

January 9, 2023, 12:07 pm

Biotech stock breaks out after upbeat lung cancer study

The shares of Novocure Ltd (NASDAQ:NVCR) are up 46% to trade at $103.72, following news that the company's experimental lung cancer therapy hit its ma...

January 5, 2023, 9:39 am

Pds biotech (pdsb) up on data from hpv-positive cancer study

A mid-stage study data shows that treatment with PDS Biotech's (PDSB) lead candidate in advanced HPV-positive cancer patients achieved a median overal...

December 29, 2022, 12:02 pm

Jefferies analyst reveals his top two biotech stocks for 2023

Moderna Inc (NASDAQ: MRNA) has tanked nearly 15% in recent days but a Jefferies analyst dubs it one of his best ideas for 2023. Moderna stock could cl...

December 27, 2022, 7:26 pm

Why is gilead sciences stock sliding tuesday? - gilead sciences (nasdaq:gild)

Gilead Sciences Inc GILD shares are trading lower Tuesday after the company reported results from its Phase 2 non-small cell lung ...

December 20, 2022, 11:30 am

Arcus biosciences, gilead shares are down after sharing data about new lung cancer drug

Shares of Arcus Biosciences Inc. RCUS, -1.23% were down 17.2% in premarket trading on Tuesday, the day after the company said the experimental treatme...

December 20, 2022, 8:47 am

Astrazeneca posts mixed results from lung cancer trial

AstraZeneca shares slipped as it reported mixed results from its latest trial (PEARL) of the cancer drug Imfinzi. Using Imfinzi as a single therapy fo...

December 19, 2022, 4:16 am

Guardant health (gh) stock sinks on disappointing blood test results

Guardant Health (NASDAQ: GH ) stock dropped nearly 33% after a test of its colon-cancer screening syste...

December 16, 2022, 9:57 am

Guardant health stock plunges, exact sciences stock soars after colorectal-cancer test study results

Shares of Guardant Health Inc. tanked 40% and shares of Exact Sciences Corp. rallied more than 25% in the extended session Thursday after Guardant ann...

December 15, 2022, 5:28 pm


Search within

Pages Search Results: